These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 18547304

  • 1. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, Serra AL.
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [Abstract] [Full Text] [Related]

  • 2. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B.
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [Abstract] [Full Text] [Related]

  • 3. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
    Truchuelo T, Díaz-Ley B, Ríos L, Alcántara J, Jaén P.
    Dermatol Online J; 2012 Jan 15; 18(1):15. PubMed ID: 22301052
    [Abstract] [Full Text] [Related]

  • 4. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
    Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I.
    Br J Dermatol; 2011 Oct 15; 165(4):912-6. PubMed ID: 21692771
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
    Micozkadioglu H, Koc Z, Ozelsancak R, Yildiz I.
    Ren Fail; 2010 Oct 15; 32(10):1233-6. PubMed ID: 20954988
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M, Bygum A, Hansen LK, Broesby-Olsen S.
    Ugeskr Laeger; 2013 Oct 21; 175(43):2569-70. PubMed ID: 24629155
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R, Neri I, Patrizi A, Angileri L, Ricci L, Magnano M.
    J Eur Acad Dermatol Venereol; 2015 Jan 21; 29(1):14-20. PubMed ID: 25174683
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M, Ohno Y, Fujita Y, Yokozeki H, Niizeki H, Ogai M, Fukai K, Nagai H, Yoshida Y, Hamada I, Hio T, Shimizu K, Murota H.
    JAMA Dermatol; 2018 Jul 01; 154(7):781-788. PubMed ID: 29800026
    [Abstract] [Full Text] [Related]

  • 16. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
    Haemel AK, O'Brian AL, Teng JM.
    Arch Dermatol; 2010 Jul 01; 146(7):715-8. PubMed ID: 20644030
    [No Abstract] [Full Text] [Related]

  • 17. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S, Roberds SL, Nakagawa J, Beresford E.
    Orphanet J Rare Dis; 2022 Sep 14; 17(1):355. PubMed ID: 36104799
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.